VACCINE TRIAL FOR GBM
Heat Shock Protein Vaccine Trial for Glioblastoma Multiforme
A clinical trial using heat shock protein vaccine (HSPPC-96) for patients
with newly diagnosed glioblastoma multiforme. Cancer immunotherapy
has emerged as an important new treatment modality, and HSPPC96 represents a novel approach to active, specific immunotherapy. The
preliminary results using HSPPC-96 have been promising, nearly doubling
life expectancy for this patient population. This vaccine trial supports the
concept of active, tumor and patient specific immunization with
autologous, tumor-derived heat-shock protein-peptide complex.
The University of Miami joins an exclusive multi-center group to complete
phase II of the study. (only 9 other Medical Centers in the country are
involved) . UM is the only center to offer this treatment in the state of
Florida.
For questions and referrals, please contact the site’s Principle Investigator:
Ricardo Jorge Komotar, M.D.
Assistant Professor of Neurological Surgery
University of Miami School of Medicine
Director of Surgical Neurooncology
University of Miami Hospital
Co-Director of Surgical Neurooncology
Sylvester Comprehensive Cancer Center
University of Miami Health Clinics
305.243.2427
rkomotar@med.miami.edu